Sarcopenia - Drug Pipeline Landscape, 2023

Sarcopenia - Drug Pipeline Landscape, 2023

Sarcopenia is a condition characterized by the loss of muscle mass and strength. It can occur due to a variety of reasons, including aging, inactivity, and certain chronic diseases.

Aging is the most common cause of sarcopenia. As people age, they tend to become less active and lose muscle mass. This process is known as age-related muscle loss or sarcopenia with aging.

Inactivity can also lead to sarcopenia. People who are not active tend to lose muscle mass and strength. This can be due to a sedentary lifestyle, bed rest, or prolonged immobilization.

A common cause of sarcopenia is lack of physical activity, low protein intake, influence of testosterone and growth hormone, changes in inflammatory cytokine, decrease in the numbers of muscle cells.

Symptoms of sarcopenia includes loss of muscle mass and strength, which can interfere with physical activities, impaired lower extremity function, basal metabolic rate (BMR) reduction, deterioration of diabetes and cardiovascular disorders etc.

Doctors most often diagnose sarcopenia after performing a physical exam and asking about symptoms. self-reported symptoms called the "SARC-F". The highest maximum SARC-F score is 10. A SARC-F score of 4 or more warrants more testing. The tests include handgrip test, Chair stand test, Walking speed test etc. Dual-energy X-ray absorptiometry (DEXA or DXA) is a type of imaging test uses low-energy X-rays to measure muscle mass, fat mass and bone density.

The main treatment path for sarcopenia is exercise. The most common investigative treatments include hormone replacement therapy which can help to raise lean body mass, decrease abdominal fat, and prevent bone deterioration in women whose hormone levels decrease with menopause and other treatment includes growth hormone supplements, testosterone supplements, hydroxy methyl butyrate, angiotensin converting enzyme inhibitors, vitamin D supplements.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Sarcopenia treatment such as BIO101, MYMD1, OC514 and others. Key players involved in the development of therapies to treat Sarcopenia are AAVogen Inc, ARMGO Pharma Inc, Biophytis, Elixir Pharma Co Ltd, OPKO Health Inc and others. Two drugs are under late-stage Phase II clinical trials and three drugs are in Phase I clinical trials and some other drugs are under preclinical, discovery and unknown stages of development.

Report Highlights

Global Insight Service's, Sarcopenia - Drug Pipeline Landscape, 2023 report provides an overview of the Sarcopenia pipeline drugs. This report covers detailed insights on Sarcopenia drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Sarcopenia pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.


The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.


The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.

1. Introduction
1.1 Sarcopenia - Pipeline Drugs, 2023 - Coverage
2. Disease Overview - Sarcopenia
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management
3. Sarcopenia - Pipeline Drugs Development - Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2023
3.3 Products under Development by Companies, 2023
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration
5. Drug Profiles
5.1 Clinical Stage Drugs - Phase II
5.1.1 BIO101
5.1.2 MYMD1
5.2 Clinical Stage Drugs - Phase I
5.2.1 OC514
5.2.2 PF1801
5.2.3 RJx-01
5.3 Early Stage Drugs - Preclinical
5.3.1 ARM-210
5.3.2 AVGN7
5.3.3 BLS-M32
5.3.4 Drug for Sarcopenia
5.3.5 Klotho protein
5.3.6 NMDP-05
5.3.7 OPK88004
5.3.8 PRG-S-3
5.3.9 Small molecule drug for sarcopenia
5.3.10 Small molecules for sarcopenia
5.3.11 Stem cell therapy for Sarcopenia
5.4 Early Stage Drugs - Discovery
5.4.1 Drug for sarcopenia
5.4.2 Drug for sarcopenia
5.4.3 DT-201
5.4.4 PB1023
5.4.5 Peptide for sarcopenia
5.5 Unknown Stage Drugs
5.5.1 KT101
5.5.2 KT102
5.5.3 KT103
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 AAVogen Inc
9.2 Anagenesis Biotechnologies SAS
9.3 ARMGO Pharma Inc
9.4 Bioleaders Corp
9.5 Biophytis
9.6 Dystrogen Therapeutics SA
9.7 Elixir Pharma Co Ltd
9.8 Encell Co Ltd
9.9 Gerologix Inc
9.10 ImmunoForge Inc.
9.11 Keren Therapeutics
9.12 Klotho Therapeutics Inc
9.13 MedAvail Holdings Inc
9.14 MyMD Pharmaceuticals, Inc.
9.15 NMD Pharma AS
9.16 Oncocross Co Ltd
9.17 OPKO Health Inc
9.18 Pephexia Therapeutics ApS
9.19 PhaseBio Pharmaceuticals Inc
9.20 PRG S&Tech Inc
9.21 Rejuvenate Biomed NV
9.22 Ridgeline Therapeutics LLC
10. Dormant Drugs
10.1 Inactive Drugs
11. Appendix
List of Tables
Table 1.1 Number of Products under Development by Sarcopenia
Table 1.2 Number of Products under Development by Companies
Table 1.3 Products under Development by Companies
Table 1.4 Products by Targets
Table 1.5 Products by Mechanism of Action
Table 1.6 Products by Molecule Type
Table 1.7 Products by Route of Administration
Table 2.1 Clinical Trial Details - BIO101/Biophytis
Table 2.2 Clinical Trial Details - MYMD1/MyMD Pharmaceuticals, Inc.
Table 3.1 Regulatory Designations
Table 4.1 Inactive Drugs
List of Figures
Figure 1.1 Number of Products under Development for Sarcopenia, 2023
Figure 1.2 Products by Top 5 Targets and Stage of Development for Sarcopenia, 2023
Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Sarcopenia, 2023
Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Sarcopenia, 2023
Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Sarcopenia, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings